Condition
Telomere Disease
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Recruiting1
Unknown1
Active Not Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03312400Phase 2CompletedPrimary
Low-Dose Danazol for the Treatment of Telomere Related Diseases
NCT07628972Phase 1Recruiting
Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)
NCT07580053Active Not Recruiting
Hereditary Influences on Pulmonary Fibrosis Trajectories
NCT04638517Phase 2Terminated
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
NCT05508321Not ApplicableUnknownPrimary
Nasal Brushing for the Diagnosis and Understanding of Telomeropathies
Showing all 5 trials